These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib-induced scrotal cutaneous side-effect. Chou CY; Wang KH; Lin YH; Lin YT; Tsai HH J Dermatol; 2013 Jan; 40(1):67-8. PubMed ID: 23078345 [No Abstract] [Full Text] [Related]
16. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Lipworth AD; Robert C; Zhu AX Oncology; 2009; 77(5):257-71. PubMed ID: 19923864 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. Lo JA; Fisher DE; Flaherty KT JAMA Oncol; 2015 Dec; 1(9):1340-1. PubMed ID: 26270186 [No Abstract] [Full Text] [Related]
18. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. McLellan B; Kerr H Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797 [TBL] [Abstract][Full Text] [Related]